TransMedics Group Past Earnings Performance

Past criteria checks 2/6

TransMedics Group has been growing earnings at an average annual rate of 20.5%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 61.4% per year. TransMedics Group's return on equity is 15.5%, and it has net margins of 8.1%.

Key information

20.5%

Earnings growth rate

35.0%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate61.4%
Return on equity15.5%
Net Margin8.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How TransMedics Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:8T8 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244013315450
30 Jun 24359314247
31 Mar 24297-1012942
31 Dec 23242-2511836
30 Sep 23192-3610731
30 Jun 23151-189327
31 Mar 23119-288125
31 Dec 2293-367027
30 Sep 2272-426027
30 Jun 2251-485426
31 Mar 2239-474525
31 Dec 2130-443822
30 Sep 2128-383221
30 Jun 2130-302820
31 Mar 2125-282417
31 Dec 2026-292419
30 Sep 2024-322421
30 Jun 2024-352521
31 Mar 2026-362622
28 Dec 1924-342420
28 Sep 1921-322217
29 Jun 1918-291815
30 Mar 1915-261514
29 Dec 1813-241214
29 Sep 1812-211014
30 Jun 189-20914
31 Mar 188-20814
30 Dec 178-21815
31 Dec 166-24816

Quality Earnings: 8T8 has a high level of non-cash earnings.

Growing Profit Margin: 8T8 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8T8 has become profitable over the past 5 years, growing earnings by 20.5% per year.

Accelerating Growth: 8T8 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 8T8 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 8T8's Return on Equity (15.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TransMedics Group, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
William PlovanicCanaccord Genuity
Kristen StewartCL King & Associates, Inc.